Murshid Al-Awady, MD
Family Medicine · Middleburg, FLNPI 1992719702
Payments from drug & device makers
Across 78 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$442
- Novo Nordisk$318
- GSK$226
- Recor Medical Inc$161
- Pfizer$99
- Amgen$69
- plus $355 from 14 others
What the payments were for
- Food & beverage$1,63998%
- Education$322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $442 |
| Novo Nordisk | 18 | $318 |
| GSK | 15 | $226 |
| Recor Medical Inc | 1 | $161 |
| Pfizer | 4 | $99 |
| Amgen | 4 | $69 |
| Bayer | 2 | $43 |
| AbbVie | 2 | $40 |
| Novartis | 1 | $34 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| Boston Scientific | 1 | $32 |
| Lilly USA, LLC | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Almatica Pharma LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,671 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $160,297 |
| JardianceEmpagliflozin | 40 | $57,687 |
| EntrestoSacubitril/Valsartan | 39 | $54,028 |
| EliquisApixaban | 49 | $53,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $46,882 |
| FarxigaDapagliflozin Propanediol | 42 | $42,331 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 38 | $42,170 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $26,947 |
| TrulicityDulaglutide | 23 | $26,825 |
| JanuviaSitagliptin Phosphate | 14 | $20,363 |
| MounjaroTirzepatide | 11 | $10,684 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $9,386 |
| XareltoRivaroxaban | 16 | $8,660 |
| Atorvastatin Calcium | 479 | $5,142 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $318 | $160,297136 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $25 | $99,85778 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $442 | $72,23892 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $226 | $56,26878 claims |
| NovartisEntresto | $34 | $54,02839 claims |
| PfizerEliquis | $99 | $53,84549 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30 | $32 | $38,75547 claims |
| Johnson & JohnsonXarelto | $12 | $8,66016 claims |
| AbbVieSynthroid | $40 | $1,11912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Middleburg
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.